Knowthestock.com
CAPR - Capricor Therapeutics Inc

Sell

Weak GrowthEarnings/Profit is Negative
WeakStrong
WeakStrong

20%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -11.55%
Operating Income is Negative
Net Income is Negative
Earnings Per Share (EPS) is Negative
Net Margin is -181.71%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 7.77
Debt Ratio is 0.15
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is NEUTRAL
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Capricor Therapeutics Inc (CAPR) - https://capricor.com/
capricor therapeutics, inc. (nasdaq: capr) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. capricor’s lead candidate, cap-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of duchenne muscular dystrophy (dmd). cap-1002 consists of allogeneic cardiosphere-derived cells, or cdcs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. cdcs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. capricor has
Exchange - NASDAQ
Industry - Research and Development in Biotechnology (except Nanobiotechnology)
Sector - Professional, Scientific, and Technical Services
CEO - Linda Marban
Employees - 73
    Close

    Login/Register

    Home


Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.